Headlines about Zosano Pharma (NASDAQ:ZSAN) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zosano Pharma earned a news impact score of 0.24 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.9262044242026 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Zosano Pharma (NASDAQ ZSAN) opened at $5.80 on Friday. The company has a market cap of $236.33, a PE ratio of -0.25 and a beta of 1.89. Zosano Pharma has a 12-month low of $5.30 and a 12-month high of $70.80.

Zosano Pharma (NASDAQ:ZSAN) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($4.00) EPS for the quarter, missing the consensus estimate of ($3.00) by ($1.00). sell-side analysts forecast that Zosano Pharma will post -18 earnings per share for the current fiscal year.

Separately, ValuEngine upgraded shares of Zosano Pharma from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st.

In other news, Director Kenneth Greathouse purchased 55,000 shares of the stock in a transaction dated Wednesday, December 6th. The stock was acquired at an average price of $0.61 per share, for a total transaction of $33,550.00. Following the completion of the transaction, the director now owns 200,000 shares of the company’s stock, valued at $122,000. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have bought 200,000 shares of company stock valued at $123,450 in the last 90 days. Insiders own 2.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://theolympiareport.com/2018/02/03/zosano-pharma-zsan-earns-daily-news-impact-rating-of-0-24.html.

About Zosano Pharma

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Insider Buying and Selling by Quarter for Zosano Pharma (NASDAQ:ZSAN)

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.